RecruitingPhase 1Phase 2NCT05607420
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)
Sponsor
Cellectis S.A.
Enrollment
80 participants
Start Date
Nov 1, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria12
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Relapsed or refractory (R/R) mature B-NHL per 2016 WHO criteria and positive for CD20 and/or CD22
- Subjects with NHL subtypes defined by WHO:
- Dose-Finding Part: R/R mature B-NHL (except chronic lymphocytic leukemia/small lymphocytic leukemia \[CLL/SLL\], Richter's transformation from prior CLL/SLL, Burkitt's lymphoma, and Waldenstrom's macroglobulinemia)
- Dose-Expansion Part: R/R LBCL, defined as:
- i. DLBCL; ii. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements; iii. Transformed FL or transformed marginal zone lymphoma (MZL); iv. Follicular lymphoma Grade 3B
- R/R disease after at least 2 lines of prior treatment, which must have included:
- An Anti-CD20 MoAb and an anthracycline for DLBCL, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, primary mediastinal large B-cell lymphoma (PMBCL), or transformed FL or MZL
- An alkylating agent in combination with an anti-CD20 MoAb for FL
- An anthracycline or bendamustine-containing chemotherapy regimen and a Bruton's tyrosine kinase (BTK) inhibitor for mantle cell lymphoma (MCL)
- Autologous anti-CD19 CAR T-cell therapy, if approved and available for the indicated lymphoma subtype, unless the subject is unable or is ineligible to receive approved autologous anti-CD19 CAR T-cell therapy (e.g., fail leukapheresis or manufacture, unable to wait for manufacture, CD19 negative disease, etc.)
- Autologous hematopoietic stem cells must be available prior to the start of the LD regimen if the subject is considered high-risk for prolonged hematologic toxicity.
Exclusion Criteria21
- Prior use of an investigational product (except for cell or gene therapies and MoAbs) within 5 half-lives or within 14 days, whichever is shorter, prior to start of LD regimen
- Previous approved therapy including chemotherapy, biologic (except MoAbs), or targeted therapy for R/R B-NHL with 5 half-lives or within 14 days, whichever is shorter, prior to start of the LD regimen
- \> 4 lines of therapy R/R B-NHL prior to start of the LD regimen.
- Prior MoAb therapy (approved or investigational) within 30 days prior to start of LD
- Prior systemic immunostimulatory agent within 3 half-lives prior to start of the LD regimen
- Prior cell or gene therapy (approved or investigational) within 6 months of the start of LD
- Prior cell or gene therapy (approved or investigational) targeting both CD20 and CD22
- Autologous HSCT infusion within 6 weeks of the start of LD
- Allogeneic HSCT within 3 months of the start of LD, or donor lymphocyte infusion within 6 weeks of the start of LD
- Active acute or chronic graft versus host disease (GvHD). Subjects should be off all immunosuppressive therapies for at least 6 weeks prior to start of LD
- Radiotherapy within 8 weeks (except for palliative radiotherapy for specific on-target lesions) (prior to start of LD regimen)
- Evidence of active central nervous system (CNS) lymphoma or previous CNS involvement of R/R B-NHL
- Presence of an active and clinically relevant CNS disorder
- Daily treatment with \>20 mg prednisone or equivalent
- Known active infection, or reactivation of a latent infection, whether bacterial or viral, fungal, mycobacterial, or other pathogens
- History of hypersensitivity to alemtuzumab
- History of neutralizing anti-drug antibody against alemtuzumab
- Any known uncontrolled cardiovascular disease within 3 months of enrollment
- Subjects requiring immunosuppressive treatment
- Major surgery within 28 days prior to start of LD
- Evidence of another uncontrolled malignancy within 2 years prior to Screening (except in situ nonmelanoma skin cell cancers and/or carcinoma in-situ of the cervix)
Interventions
BIOLOGICALUCART20x22
Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen
BIOLOGICALCLLS52
A monoclonal antibody that recognizes a CD52 antigen
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05607420
Related Trials
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
NCT0623022499 locations
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
NCT050986131 location
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT066939731 location